References
- The Japan Menopause Society. Views about the ‘Report on early termination of estrogen monotherapy in WHI’ and the current concept of HRT in Japan. Jpn Menopause Soc April, 2004; 120–123
- Naftolin F, Schneider H P, Sturdee D W, Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004; 7: 8–11
- Board of the International Menopause Society, Pines A, Sturdee D W, Birkhäuser M H, Schneider H P, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
- North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11: 11–33
- North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168–182
- Tan D, Darmasetiawan S, Haines C J, et al. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. Climacteric 2006; 9: 146–151
- Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15: 35–44
- Salpeter S R, Walsh J M, Greyber E, Ormiston T M, Salpeter E E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804
- Hsia J, Langer R D, Manson J E, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
- Hodis H N, Mack W J. Postmenopausal hormone therapy in clinical perspective. Menopause 2007; 14: 944–957
- Birkhäuser M H, Panay N, Archer D F, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11: 108–123
- Mizuguchi H, Fujimoto S, Sato K, et al. Phase II clinical study of RG83933 transdermal estradiol delivery system: dose-finding study. Rinsho Hyoka 1997; 25: 23–42
- Notelovitz M, Lenihan J P, McDermott M, Kerber I J, Nanavati N, Arce J-C. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95: 726–731
- Notelovitz M, Mattox J H. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000; 7: 310–317
- Panay N, Ylikorkala O, Archer D F, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 123–131
- Bachmann G A, Schaefers M, Uddin A, Utian W H. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007; 110: 771–779
- Haines C J, Xing S M, Park K H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 264–276
- Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 35–51
- Limpaphayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Climacteric 2006; 9: 204–214